Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART

Calza, Leonardo; Manfredi, Roberto; Chiodo, Francesco

doi:10.1097/00002030-200304110-00010

Cited by 111 publications

(82 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…435 Fibrates and fish oil may be prescribed when HTG is predominant. 436 Use of bile acid sequestrants is not recommended because they increase TGs and their effects on the absorption of antiretroviral drugs have not been studied. There are no data on the effects of statins, ezetimibe or fibrates on CV events in dyslipidaemic HIV-infected patients.…”

Section: Human Immunodeficiency Virus Patientsmentioning

confidence: 99%

ESC/EAS Guidelines for the management of dyslipidaemias

Catapano¹,

Reiner²,

Backer³

et al. 2011

Atherosclerosis

565

189

View full text Add to dashboard Cite

Section: Human Immunodeficiency Virus Patientsmentioning

confidence: 99%

ESC/EAS Guidelines for the management of dyslipidaemias

Catapano¹,

Reiner²,

Backer³

et al. 2011

Atherosclerosis

565

189

View full text Add to dashboard Cite

“…Second, the use of HAART promoted an increase in life expectancy, which may give patients the opportunity of developing osteonecrosis due to other factors. Nevertheless, HAART may contribute to the development of osteonecrosis by secondary effects on lipids (2,17).…”

Section: Discussionmentioning

confidence: 99%

“…Prevention of osteonecrosis is achieved by judicious use of corticosteroids and megestrol acetate, treatment of dyslipidemia, anticoagulant therapy in hypercoagulable states and avoiding ethanol abuse (17). Table 3.…”

Section: Discussionmentioning

confidence: 99%

Osteonecrosis in patients with acquired immunodeficiency syndrome (AIDS): report of two cases and review of the literature

Lima

Verdeal

Farias

2005

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOOsteonecrose em Pacientes Com Síndrome de Imunodeficiência Humana Adquirida (SIDA): Relato de Dois Casos e Revisão da Literatura. Um aumento na incidência de anormalidades no metabolismo ósseo-mineral (osteopenia/osteoporose) tem sido observado em pacientes com síndrome de imunodeficiência humana adquirida (SIDA). Relatamos dois casos de osteonecrose em pacientes com SIDA. Ambos os pacientes estavam recebendo terapia anti-retroviral de alta potência (HAART) e apresentavam um ou mais fatores de risco conhecidos para osteonecrose. Nós revisamos a literatura e discutimos a patogênese, diagnóstico, prevenção e tratamento desta patologia em pacientes com SIDA. ABSTRACTAn increase in the incidence of abnormalities on bone and mineral metabolism (osteopenia/osteoporosis) and the development of osteonecrosis has been observed in patients with acquired immunodeficiency syndrome (AIDS). Two cases of osteonecrosis in patients with AIDS are reported. Both patients were receiving highly active antiretroviral therapy (HAART) and presented with one or more known risk factors for osteonecrosis. We review the literature and discuss the pathogenesis, diagnosis, prevention and treatment of this entity in patients with AIDS.

show abstract

“…Reductions in lipid levels with lipid-lowering therapy are greater in non-HIV infected patients than in HIV positive subjects (Martinez et al, 2008;Silverberg et al, 2009). Many studies that evaluated the effect of statins for the treatment of antiretroviral-associated dyslipidemia have shown only partial responses to such therapy, with total and LDL-c values being reduced by about 25% (Calza et al, 2003;Silverberg et al, 2009). The effectiveness and toxicity of statins among HIV-infected individuals may differ from those of the general population for several reasons.…”

Section: Ezetimibementioning

confidence: 99%